Immunovant Inc - Asset Resilience Ratio

Latest as of September 2019: 98.50%

Immunovant Inc (IMVT) has an Asset Resilience Ratio of 98.50% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Immunovant Inc total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$116.02 Million
Cash + Short-term Investments

Total Assets

$117.79 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Immunovant Inc's Asset Resilience Ratio has changed over time. See Immunovant Inc (IMVT) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Immunovant Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMVT market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $116.02 Million 98.5%
Total Liquid Assets $116.02 Million 98.50%

Asset Resilience Insights

  • Very High Liquidity: Immunovant Inc maintains exceptional liquid asset reserves at 98.50% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Immunovant Inc Industry Peers by Asset Resilience Ratio

Compare Immunovant Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Immunovant Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Immunovant Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points

About Immunovant Inc

NASDAQ:IMVT USA Biotechnology
Market Cap
$5.52 Billion
Market Cap Rank
#3469 Global
#1177 in USA
Share Price
$27.12
Change (1 day)
-0.09%
52-Week Range
$13.78 - $29.49
All Time High
$52.71
About

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more